<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.0 Transitional//EN" "http://www.w3.org/TR/REC-html40/loose.dtd">
<html><body><html><body><section class="summaryOfFindings"><div class="section-header section-collapse-header" id="CD002779-sec-0022" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"><div class="section-header" id="CD002779-sec-0022"></div> <div class="table" id="CD002779-tbl-0001"> <a href="#0" class="open-table-viewer open-in-figure-viewer">Open in table viewer</a><div class="table-heading">
<span class="table-label">Summary of findings for the main comparison.</span>Â <span class="table-title">Antidepressants versus placebo for treating people with burning mouth syndrome</span>
</div>
<table class="summary-of-findings framed">
<tbody>
<tr class="table-header separated">
<td align="" valign="" colspan="7" rowspan="1" class="table-header"> <p><b> Antidepressants compared with placebo for treating burning mouth syndrome</b> </p> </td> </tr>
<tr class="separated">
<td align="" valign="" colspan="7" rowspan="1" bgcolor="#ffffff"> <p><b>Patient or population:</b> people diagnosed with burning mouth syndrome </p> <p><b>Settings:</b> secondary care </p> <p><b>Intervention:</b> antidepressants (trazodone) </p> <p><b>Comparison:</b> placebo </p> </td> </tr>
<tr class="table-header separated">
<td align="" valign="top" colspan="1" rowspan="3" class="table-header"> <p><b>Outcomes</b> </p> </td> <td align="" valign="top" colspan="2" rowspan="1" class="table-tint table-highlight"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </td> <td align="" valign="top" colspan="1" rowspan="3" class="table-header"> <p><b>Relative effect<br> (95% CI)</b> </p> </td> <td align="" valign="top" colspan="1" rowspan="3" class="table-header"> <p><b>Number of participants<br> (studies)</b> </p> </td> <td align="" valign="top" colspan="1" rowspan="3" class="table-header"> <p><b>Quality of the evidence<br> (GRADE)</b> </p> </td> <td align="" valign="top" colspan="1" rowspan="3" class="table-header"> <p><b>Comments</b> </p> </td> </tr>
<tr class="table-header separated">
<td align="" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p><b>Assumed risk</b> </p> </td> <td align="" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p><b>Corresponding risk</b> </p> </td> </tr>
<tr class="table-header separated">
<td align="" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p><b>Placebo</b> </p> </td> <td align="" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p><b>Antidepressants</b> </p> </td> </tr>
<tr class="separated">
<td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Symptom relief:</b> shortâterm (â¤ 3 months) </p> <p>â Mean VAS pain score <br> (Scale 0â10: lower better) </p> </td> <td align="" valign="" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>4.66</p> </td> <td align="" valign="" colspan="1" rowspan="1" class="table-tint table-highlight"> <p><b>1.26 higher</b> (0.24 lower to 2.76 higher) </p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>â</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>37<br> (1 RCT) </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>ââââ<br><b>very low</b><sup>1</sup></p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Only trazodone was assessed by a single study<br> No data were available to estimate longâterm symptom relief<br> No data were available to estimate the effect of other antidepressants </p> </td> </tr>
<tr class="separated">
<td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Change in quality of life (QoL):</b> shortâterm (â¤ 3 months) â Mean Beck Depression Inventory score(Scale 0â63: lower better) </p> </td> <td align="" valign="" colspan="3" rowspan="1" class="table-tint table-highlight"> <p>This single study narratively reported that both intervention and placebo participants were less depressed at trial completion, but there was no evidence of a difference between groups </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>37</p> <p>(1 RCT)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>ââââ<br><b>very low</b><sup>2</sup></p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Single study assessing trazodone</p> <p>No data were available to estimate longâterm change in QoL</p> </td> </tr>
<tr class="separated">
<td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Change in taste</b> </p> </td> <td align="" valign="" colspan="6" rowspan="1" class="table-tint table-highlight"> <p>No included studies reported change in taste</p> </td> </tr>
<tr class="separated">
<td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Change in feeling of dryness</b> </p> </td> <td align="" valign="" colspan="6" rowspan="1" class="table-tint table-highlight"> <p>No included studies reported change in feeling of dryness</p> </td> </tr>
<tr class="separated">
<td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Adverse effects</b> </p> </td> <td align="" valign="" colspan="3" rowspan="1" class="table-tint table-highlight"> <p>There was evidence of an increase in dizziness (RR 11.61, 95% CI 1.66 to 81.04) and drowsiness (RR 4.75, 95% CI 1.18 to 19.07) in people treated with antidepressants </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>37<br> (1 RCT) </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>ââââ<br><b>very low</b><sup>3</sup></p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Only trazodone was assessed by a single study</p> <p>No data were available to estimate the harms of other antidepressants</p> </td> </tr>
<tr class="separated">
<td align="" valign="" colspan="7" rowspan="1" bgcolor="#ffffff"> <p>*The basis for the <b>assumed risk</b> is provided in footnotes. The <b>corresponding risk</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI)<br><b>CI:</b> confidence interval; <b>OIS:</b> optimal information size; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio; <b>VAS:</b> visual analogue scale </p> </td> </tr>
<tr class="separated">
<td align="" valign="" colspan="7" rowspan="1" bgcolor="#ffffff"> <p>GRADE Working Group grades of evidence<br><b>High quality:</b> further research is very unlikely to change our confidence in the estimate of effect<br><b>Moderate quality:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate<br><b>Low quality:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate<br><b>Very low quality:</b> we are very uncertain about the estimate </p> </td> </tr>
</tbody>
<tfoot><tr>
<td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Assumed placebo risk based on mean placebo group pain score at shortâterm (â¤ 3 months) followâup; downgraded once due to risk of bias: unclear risk of attrition and reporting biases; downgraded once due to indirectness: concerns relating to applicability, only 1 type of antidepressant assessed, effects of other antidepressants may differ; downgraded twice due to imprecision: OIS not met, and 95% CI includes no effect.<br><sup>2</sup>Downgraded once due to unclear risk of attrition and reporting biases; downgraded twice due to indirectness: use of surrogate measure, and also concerns relating to applicability (only 1 type of antidepressant assessed, effects of other antidepressants may differ); downgraded once due to imprecision: OIS not met.<br><sup>3</sup>Downgraded once due to risk of bias: unclear risk of attrition and reporting biases; downgraded once due to indirectness: concerns relating to applicability, only 1 type of antidepressant assessed, effects of other antidepressants may differ; downgraded twice due to imprecision: OIS not met, and narrative report did not permit estimation of effect or 95% CI. </p> </div> </td> </tr></tfoot>
</table>
</div> <div class="table" id="CD002779-tbl-0002"> <a href="#0" class="open-table-viewer open-in-figure-viewer">Open in table viewer</a><div class="table-heading">
<span class="table-label">Summary of findings 2.</span>Â <span class="table-title">Anticonvulsants versus placebo for treating people with burning mouth syndrome</span>
</div>
<table class="summary-of-findings framed">
<tbody>
<tr class="table-header separated">
<td align="" valign="" colspan="7" rowspan="1" class="table-header"> <p><b> Anticonvulsants compared with placebo for treating burning mouth syndrome</b> </p> </td> </tr>
<tr class="separated">
<td align="" valign="" colspan="7" rowspan="1" bgcolor="#ffffff"> <p><b>Patient or population:</b> people diagnosed with burning mouth syndrome </p> <p><b>Settings:</b> secondary care </p> <p><b>Intervention:</b> anticonvulsants (gabapentin: +/â alpha lipoic acid (ALA)) </p> <p><b>Comparison:</b> placebo </p> </td> </tr>
<tr class="table-header separated">
<td align="" valign="top" colspan="1" rowspan="3" class="table-header"> <p><b>Outcomes</b> </p> </td> <td align="" valign="top" colspan="2" rowspan="1" class="table-tint table-highlight"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </td> <td align="" valign="top" colspan="1" rowspan="3" class="table-header"> <p><b>Relative effect<br> (95% CI)</b> </p> </td> <td align="" valign="top" colspan="1" rowspan="3" class="table-header"> <p><b>Number of participants<br> (studies)</b> </p> </td> <td align="" valign="top" colspan="1" rowspan="3" class="table-header"> <p><b>Quality of the evidence<br> (GRADE)</b> </p> </td> <td align="" valign="top" colspan="1" rowspan="3" class="table-header"> <p><b>Comments</b> </p> </td> </tr>
<tr class="table-header separated">
<td align="" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p><b>Assumed risk</b> </p> </td> <td align="" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p><b>Corresponding risk</b> </p> </td> </tr>
<tr class="table-header separated">
<td align="" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p><b>Placebo</b> </p> </td> <td align="" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p><b>Anticonvulsants</b> </p> </td> </tr>
<tr class="separated">
<td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Symptom relief:</b> shortâterm (â¤ 3 months) </p> <p>â Bespoke geographical burning distribution numerical scale (0â4) (Dichotomised)</p> </td> <td align="" valign="" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>150 per 1000</p> </td> <td align="" valign="" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>600 per 1000<br> (313 to 1000) </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>RR 4.00<br> (2.09 to 7.67) </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>100<br> (1 RCT) </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>ââââ<br><b>very low</b><sup>1</sup></p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No data were available to estimate longâterm symptom relief</p> <p>Only gabapentin (+/â adjunctive ALA) was assessed by a single study</p> <p>No data were available to estimate the effect of other anticonvulsants</p> </td> </tr>
<tr class="separated">
<td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Change in quality of life (QoL)</b> </p> </td> <td align="" valign="" colspan="6" rowspan="1" class="table-tint table-highlight"> <p>No included studies reported change in QoL</p> </td> </tr>
<tr class="separated">
<td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Change in taste</b> </p> </td> <td align="" valign="" colspan="6" rowspan="1" class="table-tint table-highlight"> <p>No included studies reported change in taste</p> </td> </tr>
<tr class="separated">
<td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Change in feeling of dryness</b> </p> </td> <td align="" valign="" colspan="6" rowspan="1" class="table-tint table-highlight"> <p>No included studies reported change in feeling of dryness</p> </td> </tr>
<tr class="separated">
<td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Adverse effects</b> </p> </td> <td align="" valign="" colspan="3" rowspan="1" class="table-tint table-highlight"> <p>There was evidence of an increase in drowsiness (RR 31.95, 95% CI 1.84 to 553.64) in people treated with gabapentin alone (1 RCT, 80 participants). This effect was not found for people treated with gabapentin + adjunctive ALA (1 RCT, 80 participants), nor was there evidence of an increase in mild headaches </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>100</p> <p>(1 RCT)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>ââââ<br><b>very low</b><sup>2</sup></p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Only gabapentin (+/â adjunctive ALA) was assessed by a single study<br> No data were available to estimate the harms of other anticonvulsants </p> </td> </tr>
<tr class="separated">
<td align="" valign="" colspan="7" rowspan="1" bgcolor="#ffffff"> <p>*The basis for the <b>assumed risk</b> is provided in footnotes. The <b>corresponding risk</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI)<br><b>CI:</b> confidence interval; <b>OIS:</b> optimal information size; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio </p> </td> </tr>
<tr class="separated">
<td align="" valign="" colspan="7" rowspan="1" bgcolor="#ffffff"> <p>GRADE Working Group grades of evidence<br><b>High quality:</b> further research is very unlikely to change our confidence in the estimate of effect<br><b>Moderate quality:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate<br><b>Low quality:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate<br><b>Very low quality:</b> we are very uncertain about the estimate </p> </td> </tr>
</tbody>
<tfoot><tr>
<td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Assumed placebo risk based on control estimate at shortâterm (â¤ 3 months) followâup: total of control participants experiencing symptom relief, divided by total number of participants in control group multiplied by 100; downgraded twice due to high risk of bias across multiple domains; downgraded once due to indirectness: concerns relating to applicability, only 1 type of anticonvulsant assessed, effects of other anticonvulsants may differ; downgraded once due to imprecision: OIS not met.<br><sup>2</sup>Single 4âarmed study (totalling 120 people), with 3 of 4 groups included in this comparison (placebo group: 60 people; gabapentin group: 20 people; gabapentin + ALA group: 20 people), the remaining group (ALA: 20 people) and placebo group (60 people) are included within <a href="./full#CD002779-tbl-0005">summary of findings Table 5</a>; downgraded twice due to high risk of bias across multiple domains; downgraded once due to indirectness: concerns relating to applicability, only 1 type of anticonvulsant assessed, effects of other anticonvulsants may differ; downgraded once due to imprecision: OIS not met. </p> </div> </td> </tr></tfoot>
</table>
</div> <div class="table" id="CD002779-tbl-0003"> <a href="#0" class="open-table-viewer open-in-figure-viewer">Open in table viewer</a><div class="table-heading">
<span class="table-label">Summary of findings 3.</span>Â <span class="table-title">Benzodiazepines versus placebo for treating people with burning mouth syndrome</span>
</div>
<table class="summary-of-findings framed">
<tbody>
<tr class="table-header separated">
<td align="" valign="" colspan="7" rowspan="1" class="table-header"> <p><b> Benzodiazepines compared with placebo for treating burning mouth syndrome</b> </p> </td> </tr>
<tr class="separated">
<td align="" valign="" colspan="7" rowspan="1" bgcolor="#ffffff"> <p><b>Patient or population:</b> people diagnosed with burning mouth syndrome </p> <p><b>Settings:</b> secondary care </p> <p><b>Intervention:</b> benzodiazepines (topical/systemic clonazepam) </p> <p><b>Comparison:</b> placebo </p> </td> </tr>
<tr class="table-header separated">
<td align="" valign="top" colspan="1" rowspan="3" class="table-header"> <p><b>Outcomes</b> </p> </td> <td align="" valign="top" colspan="2" rowspan="1" class="table-tint table-highlight"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </td> <td align="" valign="top" colspan="1" rowspan="3" class="table-header"> <p><b>Relative effect<br> (95% CI)</b> </p> </td> <td align="" valign="top" colspan="1" rowspan="3" class="table-header"> <p><b>Number of participants<br> (studies)</b> </p> </td> <td align="" valign="top" colspan="1" rowspan="3" class="table-header"> <p><b>Quality of the evidence<br> (GRADE)</b> </p> </td> <td align="" valign="top" colspan="1" rowspan="3" class="table-header"> <p><b>Comments</b> </p> </td> </tr>
<tr class="table-header separated">
<td align="" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p><b>Assumed risk</b> </p> </td> <td align="" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p><b>Corresponding risk</b> </p> </td> </tr>
<tr class="table-header separated">
<td align="" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p><b>Placebo</b> </p> </td> <td align="" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p><b> Benzodiazepines</b> </p> </td> </tr>
<tr class="separated">
<td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Symptom relief:</b> shortâterm (â¤ 3 months) </p> <p>â Mean VAS pain score <br> (Scale 0â10: lower better) </p> </td> <td align="" valign="" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>4.76</p> </td> <td align="" valign="" colspan="1" rowspan="1" class="table-tint table-highlight"> <p><b>1.89 lower</b> (2.19 to 1.59 lower) </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>â</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>111<br> (2 RCTs) </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>ââââ<br><b>very low</b><sup>1</sup></p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>There was evidence of a difference between subgroups between the 2 subgroups: systemic and topical clonazepam </p> <p>Shortâterm relief is estimated from 2 <b>topical clonazepam</b> studies. Longâterm symptom relief (&gt; 3 to â¤ 6 months) was <b>1.39 lower</b> (1.96 to 0.83 lower) than the placebo group (1 RCT, 66 participants) </p> <p>No evidence of shortâterm symptom relief from a single study assessing <b>systemic clonazepam</b> (â¤ 3 months): mean VAS score in both placebo and intervention groups was 4.5 (MD <b>0.00 lower</b>, 95% CI 1.86 lower to 1.86 higher) (1 RCT, 20 participants) </p> <p>No data were available to estimate the effect of other benzodiazepines</p> </td> </tr>
<tr class="separated">
<td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Change in quality of life (QoL):</b> shortâterm (â¤ 3 months) â Mean depression score(Scale 0â4: lower better) </p> </td> <td align="" valign="" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>0.8</p> </td> <td align="" valign="" colspan="1" rowspan="1" class="table-tint table-highlight"> <p><b>0.20 lower</b> (0.95 lower to 0.55 higher) </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>â</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>20<br> (1 RCT) </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>ââââ<br><b>very low</b><sup>2</sup></p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Single study assessing systemic clonazepam<br> No data were available to estimate longâterm change in QoL </p> </td> </tr>
<tr class="separated">
<td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Change in taste:</b> shortâterm (â¤ 3 months) </p> <p>â Mean taste test score (Scale 0â16: higher better)</p> </td> <td align="" valign="" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>12.3</p> </td> <td align="" valign="" colspan="1" rowspan="1" class="table-tint table-highlight"> <p><b>1.00 lower</b> (3.11 lower to 1.11 higher) </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>â</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>20<br> (1 RCT) </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>ââââ<br><b>very low</b><sup>3</sup></p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Single study assessing systemic clonazepam</p> <p>No data were available to estimate longâterm change in taste</p> </td> </tr>
<tr class="separated">
<td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Change in feeling of dryness</b> </p> </td> <td align="" valign="" colspan="6" rowspan="1" class="table-tint table-highlight"> <p>No included studies reported change in feeling of dryness</p> </td> </tr>
<tr class="separated">
<td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Adverse effects</b> </p> </td> <td align="" valign="" colspan="4" rowspan="1" class="table-tint table-highlight"> <p>There was no difference in the adverse events reported (drowsiness: 2 RCTs, 114 participants; dry mouth, spasmophilia, or euphoric behaviour: 1 RCT, 48 participants) for people treated with benzodiazepines </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>ââââ<br><b>very low</b><sup>4</sup></p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Both studies used topical clonazepam</p> <p>We were unable to estimate the harms of systemic clonazepam as adverse events were not reported by its study<br> No data were available to estimate the harms of other benzodiazepines </p> </td> </tr>
<tr class="separated">
<td align="" valign="" colspan="7" rowspan="1" bgcolor="#ffffff"> <p>*The basis for the <b>assumed risk</b> is provided in footnotes. The <b>corresponding risk</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI)<br><b>CI:</b> confidence interval; <b>MD:</b> mean difference; <b>OIS:</b> optimal information size; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio; <b>VAS:</b> visual analogue scale </p> </td> </tr>
<tr class="separated">
<td align="" valign="" colspan="7" rowspan="1" bgcolor="#ffffff"> <p>GRADE Working Group grades of evidence<br><b>High quality:</b> further research is very unlikely to change our confidence in the estimate of effect<br><b>Moderate quality:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate<br><b>Low quality:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate<br><b>Very low quality:</b> we are very uncertain about the estimate </p> </td> </tr>
</tbody>
<tfoot><tr>
<td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Assumed placebo risk based on mean placebo group pain score at shortâterm (â¤ 3 months) followâup; downgraded once due to studies being assessed at unclear risk of bias across multiple domains; downgraded once due to inconsistency: substantial heterogeneity (I<sup>2</sup> = 56%); downgraded once due to indirectness: concerns relating to applicability, only 1 type of benzodiazepine (clonazepam â irrespective of mode of administration) assessed, effects of other benzodiazepines may differ; downgraded once due to imprecision: OIS not met.<br><sup>2</sup>Assumed placebo risk based on mean placebo group depression score at shortâterm (â¤ 3 months) followâup; downgraded once due to high risk of selective reporting bias; downgraded twice due to indirectness: use of surrogate measure, and also concerns relating to applicability, only 1 type of benzodiazepine (clonazepam â irrespective of mode of administration) assessed, effects of other benzodiazepines may differ; downgraded twice due to imprecision: OIS not met, and 95% CI includes no effect.<br><sup>3</sup>Assumed placebo risk based on mean placebo group taste score at shortâterm (â¤ 3 months) followâup; downgraded once due to indirectness: concerns relating to applicability, only 1 type of benzodiazepine (clonazepam â irrespective of mode of administration) assessed, effects of other benzodiazepines may differ; downgraded once due to high risk of selective reporting bias; downgraded twice due to imprecision: OIS not met, and 95% CI includes no effect.<br><sup>4</sup>Downgraded once due to studies being assessed at unclear risk of bias across multiple domains; downgraded once due to indirectness: concerns relating to applicability, only 1 type of benzodiazepine (clonazepam â irrespective of mode of administration) assessed, effects of other benzodiazepines may differ; downgraded twice due to imprecision: OIS not met, and 95% CI includes no effect. </p> </div> </td> </tr></tfoot>
</table>
</div> <div class="table" id="CD002779-tbl-0004"> <a href="#0" class="open-table-viewer open-in-figure-viewer">Open in table viewer</a><div class="table-heading">
<span class="table-label">Summary of findings 4.</span>Â <span class="table-title">Cholinergics versus placebo for treating people with burning mouth syndrome</span>
</div>
<table class="summary-of-findings framed">
<tbody>
<tr class="table-header separated">
<td align="" valign="" colspan="7" rowspan="1" class="table-header"> <p><b> Cholinergics compared with placebo for treating burning mouth syndrome</b> </p> </td> </tr>
<tr class="separated">
<td align="" valign="" colspan="7" rowspan="1" bgcolor="#ffffff"> <p><b>Patient or population:</b> people diagnosed with burning mouth syndrome </p> <p><b>Settings:</b> secondary care </p> <p><b>Intervention:</b> cholinergics (bethanechol) </p> <p><b>Comparison:</b> placebo </p> </td> </tr>
<tr class="table-header separated">
<td align="left" valign="top" colspan="1" rowspan="3" class="table-header"> <p><b>Outcomes</b> </p> </td> <td align="left" valign="top" colspan="2" rowspan="1" class="table-tint table-highlight"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </td> <td align="left" valign="top" colspan="1" rowspan="3" class="table-header"> <p><b>Relative effect<br> (95% CI)</b> </p> </td> <td align="left" valign="top" colspan="1" rowspan="3" class="table-header"> <p><b>Number of participants<br> (studies)</b> </p> </td> <td align="left" valign="top" colspan="1" rowspan="3" class="table-header"> <p><b>Quality of the evidence<br> (GRADE)</b> </p> </td> <td align="left" valign="top" colspan="1" rowspan="3" class="table-header"> <p><b>Comments</b> </p> </td> </tr>
<tr class="table-header separated">
<td align="left" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p><b>Assumed risk</b> </p> </td> <td align="left" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p><b>Corresponding risk</b> </p> </td> </tr>
<tr class="table-header separated">
<td align="left" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p><b>Placebo</b> </p> </td> <td align="left" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p><b>Cholinergics</b> </p> </td> </tr>
<tr class="separated">
<td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Symptom relief:</b> shortâterm (â¤ 3 months) </p> <p>â Bespoke BMS symptomology change scale (Dichotomised)</p> </td> <td align="" valign="" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>150 per 1000</p> </td> <td align="" valign="" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>750 per 1000<br> (39 to 1000) </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>RR 5.00<br> (0.26 to 98.00) </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>40<br> (1 RCT) </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>ââââ<br><b>very low</b><sup>1</sup></p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No data were available to estimate longâterm symptom relief<br> Only bethanechol was assessed by a single study<br> No data were available to estimate the effect of other cholinergics </p> </td> </tr>
<tr class="separated">
<td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Change in quality of life (QoL)</b> </p> </td> <td align="" valign="" colspan="6" rowspan="1" class="table-tint table-highlight"> <p>No included studies reported change in QoL</p> </td> </tr>
<tr class="separated">
<td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Change in taste</b> </p> </td> <td align="" valign="" colspan="6" rowspan="1" class="table-tint table-highlight"> <p>No included studies reported change in taste</p> </td> </tr>
<tr class="separated">
<td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Change in feeling of dryness</b> </p> </td> <td align="" valign="" colspan="6" rowspan="1" class="table-tint table-highlight"> <p>No included studies reported change in feeling of dryness</p> </td> </tr>
<tr class="separated">
<td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Adverse effects</b> </p> </td> <td align="" valign="" colspan="3" rowspan="1" class="table-tint table-highlight"> <p>This single study narratively reported adverse effect data. 4 participants (20%) in the bethanechol arm reported adverse events (nausea, dizziness, blood pressure fall, cold perspiration or sporadic abdominal pain). Reported data did not present the distribution of these outcomes by participant </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>40<br> (1 RCT) </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>ââââ<br><b>very low</b><sup>2</sup></p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Only bethanechol was assessed by a single study<br> No data were available to estimate the harms of other cholinergics </p> </td> </tr>
<tr class="separated">
<td align="" valign="" colspan="7" rowspan="1" bgcolor="#ffffff"> <p>*The basis for the <b>assumed risk</b> is provided in footnotes. The <b>corresponding risk</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI)<br><b>BMS:</b> burning mouth syndrome; <b>CI:</b> confidence interval; <b>OIS:</b> optimal information size; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio </p> </td> </tr>
<tr class="separated">
<td align="" valign="" colspan="7" rowspan="1" bgcolor="#ffffff"> <p>GRADE Working Group grades of evidence<br><b>High quality:</b> further research is very unlikely to change our confidence in the estimate of effect<br><b>Moderate quality:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate<br><b>Low quality:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate<br><b>Very low quality:</b> we are very uncertain about the estimate </p> </td> </tr>
</tbody>
<tfoot><tr>
<td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>No placebo group participants experienced pain relief in the single study assessing cholinergics. Consequently, in order to calculate the corresponding risk, the assumed placebo risk for cholinergics is based on the assumed placebo risk for anticonvulsants, as detailed in <a href="./full#CD002779-tbl-0002">summary of findings Table 2</a>; downgraded twice: risk of bias concerns across multiple domains (allocation, blinding, selective reporting and absence of baseline data); downgraded once due to indirectness: concerns relating to applicability, only 1 type of anticholinergic assessed, effects of other cholinergics may differ; downgraded twice due to imprecision: OIS not met, and 95% CI includes no effect.<br><sup>2</sup>Downgraded twice: risk of bias concerns across multiple domains (allocation, blinding, selective reporting and absence of baseline data); downgraded once due to indirectness: concerns relating to applicability, only 1 type of anticholinergic assessed, effects of other cholinergics may differ; downgraded twice due to imprecision: OIS not met, and narrative report did not permit estimation of effect or 95% CI. </p> </div> </td> </tr></tfoot>
</table>
</div> <div class="table" id="CD002779-tbl-0005"> <a href="#0" class="open-table-viewer open-in-figure-viewer">Open in table viewer</a><div class="table-heading">
<span class="table-label">Summary of findings 5.</span>Â <span class="table-title">Dietary supplements versus placebo for treating people with burning mouth syndrome</span>
</div>
<table class="summary-of-findings framed">
<tbody>
<tr class="table-header separated">
<td align="" valign="" colspan="7" rowspan="1" class="table-header"> <p><b> Dietary supplements compared with placebo for treating burning mouth syndrome</b> </p> </td> </tr>
<tr class="separated">
<td align="" valign="" colspan="7" rowspan="1" bgcolor="#ffffff"> <p><b>Patient or population:</b> people diagnosed with burning mouth syndrome </p> <p><b>Settings:</b> secondary care </p> <p><b>Intervention:</b> dietary supplements (ALA with (+ vitamins, + lycopene + green tea extract) or without adjunctive active ingredients; hypericum perforatum (St John's Wort); 'Catuama' herbal compound; lycopene) </p> <p><b>Comparison:</b> placebo </p> </td> </tr>
<tr class="table-header separated">
<td align="left" valign="top" colspan="1" rowspan="3" class="table-header"> <p><b>Outcomes</b> </p> </td> <td align="left" valign="top" colspan="2" rowspan="1" class="table-tint table-highlight"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </td> <td align="left" valign="top" colspan="1" rowspan="3" class="table-header"> <p><b>Relative effect<br> (95% CI)</b> </p> </td> <td align="left" valign="top" colspan="1" rowspan="3" class="table-header"> <p><b>Number of participants<br> (studies)</b> </p> </td> <td align="left" valign="top" colspan="1" rowspan="3" class="table-header"> <p><b>Quality of the evidence<br> (GRADE)</b> </p> </td> <td align="left" valign="top" colspan="1" rowspan="3" class="table-header"> <p><b>Comments</b> </p> </td> </tr>
<tr class="table-header separated">
<td align="left" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p><b>Assumed risk</b> </p> </td> <td align="left" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p><b>Corresponding risk</b> </p> </td> </tr>
<tr class="table-header separated">
<td align="left" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p><b>Placebo</b> </p> </td> <td align="left" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p><b>Dietary supplements</b> </p> </td> </tr>
<tr class="separated">
<td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Symptom relief:</b> shortâterm (â¤ 3 months) </p> </td> <td align="" valign="" colspan="3" rowspan="1" class="table-tint table-highlight"> <p>There is insufficient or contradictory evidence regarding the benefit of any of the evaluated dietary supplements over placebo to evaluate shortâterm symptom relief </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>628<br> (12 RCTs) </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>ââââ<br><b>very low</b><sup>1</sup></p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Interventions evaluated for shortâterm symptom relief included:</p> <p> </p>
<ul id="CD002779-list-0001">
<li> <p>ALA without adjunctive active ingredients (3 RCTs)</p> </li> <li> <p>ALA with vitamins (5 RCTs)</p> </li> <li> <p>ALA with lycopene and green tea extract (2 RCTs)</p> </li> <li> <p>hypericum perforatum (St John's Wort) (1 RCT)</p> </li> <li> <p>'Catuama' herbal compound (1 RCT)</p> </li> <li> <p>lycopene (1 RCT)</p> </li> </ul>
<p></p> <p>The mean VAS pain score (scale 0â10: lower better) for <b>longâterm symptom relief</b> (&gt; 3 to â¤ 6 months) was <b>0.89 lower</b> (2.37 lower to 0.59 higher) for people treated with ALA (with or without adjunctive vitamins) than the placebo group (2 RCTs, 94 participants) </p> </td> </tr>
<tr class="separated">
<td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Change in quality of life (QoL):</b> shortâterm (â¤ 3 months) </p> <p>â Mean OHIPâ14 score (Scale 0â70: lower better)</p> </td> <td align="" valign="" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>17.38</p> </td> <td align="" valign="" colspan="1" rowspan="1" class="table-tint table-highlight"> <p><b>0.93 higher</b> (3.14 lower to 5.00 higher) </p> </td> <td align="" valign="" colspan="1" rowspan="3" bgcolor="#ffffff"> <p>â</p> </td> <td align="" valign="" colspan="1" rowspan="3" bgcolor="#ffffff"> <p>50<br> (1 RCT) </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>ââââ<br><b>very low</b><sup>2</sup></p> </td> <td align="" valign="" colspan="1" rowspan="3" bgcolor="#ffffff"> <p>Single study assessing shortâterm QoL, anxiety and depression compared lycopene with placebo </p> <p>No data were available to estimate longâterm change in QoL, or its surrogate markers: anxiety or depression </p> <p>No data were available to estimate the effect of other dietary supplements; however, 1 study (43 patients), comparing hypericum perforatum extract with placebo, evaluated QoL from patient selfâreports and narratively indicated that both intervention and placebo participants were better able to cope at trial completion </p> </td> </tr>
<tr class="separated">
<td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Change in QoL â anxiety:</b> shortâterm (â¤ 3 months) </p> <p>â Mean HAD anxiety score (Scale 0â21: lower better)</p> </td> <td align="" valign="" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>11.5</p> </td> <td align="" valign="" colspan="1" rowspan="1" class="table-tint table-highlight"> <p><b>2.85 lower</b> (5.28 to 0.42 lower) </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>ââââ<br><b>very low</b><sup>3</sup></p> </td> </tr>
<tr class="separated">
<td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Change in QoL â depression:</b> shortâterm (â¤ 3 months) </p> <p>â Mean HAD depression score (Scale 0â21: lower better)</p> </td> <td align="" valign="" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>6.25</p> </td> <td align="" valign="" colspan="1" rowspan="1" class="table-tint table-highlight"> <p><b>1.87 lower</b> (4.23 lower to 0.49 higher) </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>ââââ<br><b>very low</b><sup>4</sup></p> </td> </tr>
<tr class="separated">
<td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Change in taste</b> </p> </td> <td align="" valign="" colspan="6" rowspan="1" class="table-tint table-highlight"> <p>No included studies reported change in taste</p> </td> </tr>
<tr class="separated">
<td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Change in feeling of dryness</b> </p> </td> <td align="" valign="" colspan="6" rowspan="1" class="table-tint table-highlight"> <p>No included studies reported change in feeling of dryness</p> </td> </tr>
<tr class="separated">
<td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Adverse effects</b> </p> </td> <td align="" valign="" colspan="4" rowspan="1" class="table-tint table-highlight"> <p> </p>
<ul id="CD002779-list-0002">
<li> <p>For people treated with ALA (with or without adjunctive active ingredients), there was evidence of an increase in headache occurrence (RR 10.87, 95% CI 1.36 to 87.03; 2 RCTs, 118 participants) or gastrointestinal complaints (RR 4.00, 95% CI 1.21 to 13.27; 3 RCTs, 138 participants). There was no difference in blood pressure (1 RCT, 38 participants) or intermittent facial skin rash (1 RCT, 80 participants) </p> </li> <li> <p>For people treated with ALA (with or without adjunctive active ingredients) or 'Catuama' herbal compound, there was no difference in drowsiness (2 RCTs, 110 participants) </p> </li> <li> <p>For people treated with 'Catuama' herbal compound (1 RCT, 72 participants), there was no difference in exacerbation of symptoms, insomnia or weight gain </p> </li> <li> <p>1 RCT (60 participants, ALA with adjunctive vitamins) reported no "notable adverse effects", and another RCT (40 participants, ALA with adjunctive vitamins) narratively reported 4 intervention participants (20%) experienced heartburn, before correction by administration of ranitidine (150 mg) </p> </li> <li> <p>Severe headache resulting from hypericum perforatum extract use caused 1 participant (5%) to discontinue treatment (1 RCT, 43 participants) </p> </li> <li> <p>4 RCTs (224 participants, ALA (with or without adjunctive active ingredients) and lycopene) narratively reported that no adverse effects occurred </p> </li> </ul>
<p></p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>ââââ<br><b>very low</b><sup>5</sup></p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> </tr>
<tr class="separated">
<td align="" valign="" colspan="7" rowspan="1" bgcolor="#ffffff"> <p>*The basis for the <b>assumed risk</b> is provided in footnotes. The <b>corresponding risk</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI)<br><b>ALA:</b> alpha lipoic acid; <b>CI:</b> confidence interval; <b>HAD:</b> Hospital Anxiety and Depression scale; <b>OHIPâ14:</b> Oral Health Impact Profileâ14; <b>OIS:</b> optimal information size; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio; <b>VAS:</b> visual analogue scale </p> </td> </tr>
<tr class="separated">
<td align="" valign="" colspan="7" rowspan="1" bgcolor="#ffffff"> <p>GRADE Working Group grades of evidence<br><b>High quality:</b> further research is very unlikely to change our confidence in the estimate of effect<br><b>Moderate quality:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate<br><b>Low quality:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate<br><b>Very low quality:</b> we are very uncertain about the estimate </p> </td> </tr>
</tbody>
<tfoot><tr>
<td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Downgraded twice due to high risk of bias across multiple domains; downgraded twice due to inconsistency between, and within, subgroups; 1 RCT (<a href="./references#CD002779-bbs2-0005">Carbone 2009</a>) contributes to 2 subgroups: ALA with vitamins and ALA without adjunctive active ingredients.<br><sup>2</sup>Assumed placebo risk based on mean placebo group QoL score at shortâterm (â¤ 3 months) followâup; downgraded once due to high risk of bias relating to selective reporting and lack of baseline data; downgraded once due to indirectness: concerns relating to applicability, only 1 type of dietary supplement assessed, effects of other dietary supplements may differ; downgraded twice due to imprecision: OIS not met, and 95% CI includes no effect.<br><sup>3</sup>Assumed placebo risk based on mean placebo group anxiety score at shortâterm (â¤ 3 months) followâup; downgraded once due to high risk of bias relating to selective reporting and lack of baseline data; downgraded twice due to indirectness: use of surrogate measure, and also concerns relating to applicability, only 1 type of dietary supplement assessed, effects of other dietary supplements may differ; downgraded once due to imprecision: OIS not met.<br><sup>4</sup>Assumed placebo risk based on mean placebo group depression score at shortâterm (â¤ 3 months) followâup; downgraded once due to high risk of bias relating to selective reporting and lack of baseline data; downgraded twice due to indirectness: use of surrogate measure, and also concerns relating to applicability, only 1 type of dietary supplement assessed, effects of other dietary supplements may differ; downgraded once due to imprecision: OIS not met.<br><sup>5</sup>Downgraded twice due to high risk of bias across multiple domains; downgraded twice due to inconsistency between, and within, subgroups; downgraded once for imprecision: wide CIs estimated around effect sizes. </p> </div> </td> </tr></tfoot>
</table>
</div> <div class="table" id="CD002779-tbl-0006"> <a href="#0" class="open-table-viewer open-in-figure-viewer">Open in table viewer</a><div class="table-heading">
<span class="table-label">Summary of findings 6.</span>Â <span class="table-title">Electromagnetic radiation versus placebo for treating people with burning mouth syndrome</span>
</div>
<table class="summary-of-findings framed">
<tbody>
<tr class="table-header separated">
<td align="" valign="" colspan="7" rowspan="1" class="table-header"> <p><b> Electromagnetic radiation compared with placebo for treating burning mouth syndrome</b> </p> </td> </tr>
<tr class="separated">
<td align="" valign="" colspan="7" rowspan="1" bgcolor="#ffffff"> <p><b>Patient or population:</b> people diagnosed with burning mouth syndrome </p> <p><b>Settings:</b> secondary care </p> <p><b>Intervention:</b> electromagnetic radiation (lowâlevel laser therapy) </p> <p><b>Comparison:</b> placebo </p> </td> </tr>
<tr class="table-header separated">
<td align="left" valign="top" colspan="1" rowspan="3" class="table-header"> <p><b>Outcomes</b> </p> </td> <td align="left" valign="top" colspan="2" rowspan="1" class="table-tint table-highlight"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </td> <td align="left" valign="" colspan="1" rowspan="3" class="table-header"> <p><b>Relative effect<br> (95% CI)</b> </p> </td> <td align="left" valign="top" colspan="1" rowspan="3" class="table-header"> <p><b>Number of participants<br> (studies)</b> </p> </td> <td align="left" valign="top" colspan="1" rowspan="3" class="table-header"> <p><b>Quality of the evidence<br> (GRADE)</b> </p> </td> <td align="left" valign="top" colspan="1" rowspan="3" class="table-header"> <p><b>Comments</b> </p> </td> </tr>
<tr class="table-header separated">
<td align="left" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p><b>Assumed risk</b> </p> </td> <td align="left" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p><b>Corresponding risk</b> </p> </td> </tr>
<tr class="table-header separated">
<td align="left" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p><b>Placebo</b> </p> </td> <td align="left" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p><b> Electromagnetic radiation</b> </p> </td> </tr>
<tr class="separated">
<td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Symptom relief:</b> </p> <p>shortâterm (â¤ 3 months)</p> <p>â Mean VAS score (Scale 0â100: lower better)</p> </td> <td align="" valign="" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>62.84</p> </td> <td align="" valign="" colspan="1" rowspan="1" class="table-tint table-highlight"> <p><b>30.36 lower</b> (44.22 to 16.50 lower) </p> </td> <td align="" valign="" colspan="1" rowspan="2" bgcolor="#ffffff"> <p>â</p> </td> <td align="" valign="" colspan="1" rowspan="2" bgcolor="#ffffff"> <p>58<br> (1 RCT) </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>ââââ<br><b>very low</b><sup>1</sup></p> </td> <td align="" valign="" colspan="1" rowspan="2" bgcolor="#ffffff"> <p>No data were available to estimate longâterm symptom relief<br> Only lowâlevel laser therapy (infrared laser and red laser) was assessed by a single study<br> No data were available to estimate the effect of other types of electromagnetic radiation (e.g. transcranial magnetic stimulation) </p> </td> </tr>
<tr class="separated">
<td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Change in quality of life (QoL):</b> </p> <p>shortâterm (â¤ 3 months)</p> <p>â Mean OHIPâ14 score (Scale 0â56: lower better)</p> </td> <td align="" valign="" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>13.39</p> </td> <td align="" valign="" colspan="1" rowspan="1" class="table-tint table-highlight"> <p><b>5.24 lower</b> (7.38 to 3.09 lower) </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>ââââ<br><b>very low</b><sup>2</sup></p> </td> </tr>
<tr class="separated">
<td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Change in taste</b> </p> </td> <td align="" valign="" colspan="6" rowspan="1" class="table-tint table-highlight"> <p>No included study reported change in taste</p> </td> </tr>
<tr class="separated">
<td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Change in feeling of dryness</b> </p> </td> <td align="" valign="" colspan="6" rowspan="1" class="table-tint table-highlight"> <p>No included study reported change in feeling of dryness</p> </td> </tr>
<tr class="separated">
<td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Adverse effects</b> </p> </td> <td align="" valign="" colspan="6" rowspan="1" class="table-tint table-highlight"> <p>No included study reported the occurrence of adverse events</p> </td> </tr>
<tr class="separated">
<td align="" valign="" colspan="7" rowspan="1" bgcolor="#ffffff"> <p>*The basis for the <b>assumed risk</b> is provided in footnotes. The <b>corresponding risk</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br><b>CI:</b> confidence interval; <b>OHIPâ14:</b> Oral Health Impact Profileâ14; <b>OIS:</b> optimal information size; <b>RCT:</b> randomised controlled trial; <b>VAS:</b> visual analogue scale </p> </td> </tr>
<tr class="separated">
<td align="" valign="" colspan="7" rowspan="1" bgcolor="#ffffff"> <p>GRADE Working Group grades of evidence<br><b>High quality:</b> further research is very unlikely to change our confidence in the estimate of effect<br><b>Moderate quality:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate<br><b>Low quality:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate<br><b>Very low quality:</b> we are very uncertain about the estimate </p> </td> </tr>
</tbody>
<tfoot><tr>
<td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Assumed placebo risk based on mean placebo group pain score at shortâterm (â¤ 3 months) followâup; downgraded once due to the single study being assessed at unclear risk of bias across multiple domains and high risk of bias relating to other bias; downgraded once due to indirectness: concerns relating to applicability, only 1 type of electromagnetic radiation assessed, effects of other types of electromagnetic radiation may differ; downgraded once due to imprecision: OIS not met.<br><sup>2</sup>Assumed placebo risk based on mean placebo group QoL score at shortâterm (â¤ 3 months) followâup; downgraded once due to the single study being assessed at unclear risk of bias across multiple domains and high risk of bias relating to other bias; downgraded once due to indirectness: concerns relating to applicability, only 1 type of electromagnetic radiation assessed, effects of other types of electromagnetic radiation may differ; downgraded once due to imprecision: OIS not met. </p> </div> </td> </tr></tfoot>
</table>
</div> <div class="table" id="CD002779-tbl-0007"> <a href="#0" class="open-table-viewer open-in-figure-viewer">Open in table viewer</a><div class="table-heading">
<span class="table-label">Summary of findings 7.</span>Â <span class="table-title">Physical barriers versus placebo for treating people with burning mouth syndrome</span>
</div>
<table class="summary-of-findings framed">
<tbody>
<tr class="table-header separated">
<td align="" valign="" colspan="7" rowspan="1" class="table-header"> <p><b> Physical barriers compared with placebo for treating burning mouth syndrome</b> </p> </td> </tr>
<tr class="separated">
<td align="" valign="" colspan="7" rowspan="1" bgcolor="#ffffff"> <p><b>Patient or population:</b> people diagnosed with burning mouth syndrome </p> <p><b>Settings:</b> secondary care </p> <p><b>Intervention:</b> physical barriers (tongue protector) </p> <p><b>Comparison:</b> placebo </p> </td> </tr>
<tr class="table-header separated">
<td align="" valign="top" colspan="1" rowspan="3" class="table-header"> <p><b>Outcomes</b> </p> </td> <td align="left" valign="top" colspan="2" rowspan="1" class="table-tint table-highlight"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </td> <td align="left" valign="top" colspan="1" rowspan="3" class="table-header"> <p><b>Relative effect<br> (95% CI)</b> </p> </td> <td align="left" valign="top" colspan="1" rowspan="3" class="table-header"> <p><b>Number of participants<br> (studies)</b> </p> </td> <td align="left" valign="top" colspan="1" rowspan="3" class="table-header"> <p><b>Quality of the evidence<br> (GRADE)</b> </p> </td> <td align="left" valign="top" colspan="1" rowspan="3" class="table-header"> <p><b>Comments</b> </p> </td> </tr>
<tr class="table-header separated">
<td align="left" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p><b>Assumed risk</b> </p> </td> <td align="left" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p><b>Corresponding risk</b> </p> </td> </tr>
<tr class="table-header separated">
<td align="left" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p><b>Placebo</b> </p> </td> <td align="left" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p><b>Physical barriers</b> </p> </td> </tr>
<tr class="separated">
<td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Symptom relief:</b> <br> shortâterm (â¤ 3 months)<br> â Mean VAS pain score (Scale 0â10: lower better) </p> </td> <td align="" valign="" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>5.6</p> </td> <td align="" valign="" colspan="1" rowspan="1" class="table-tint table-highlight"> <p><b>1.10 lower</b> (2.14 to 0.06 lower) </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>â</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>50<br> (1 RCT) </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>ââââ<br><b>very low</b><sup>1</sup></p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Single study assessing tongue protectors<br> No data were available to estimate longâterm symptom relief </p> </td> </tr>
<tr class="separated">
<td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Change in quality of life (QoL):</b> shortâterm (â¤ 3 months)<br> â Mean OHIPâ49 score (Scale 0â196: lower better) </p> </td> <td align="" valign="" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>53.72</p> </td> <td align="" valign="" colspan="1" rowspan="1" class="table-tint table-highlight"> <p><b>9.20 lower</b> (26.90 lower to 8.50 higher) </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>â</p> </td> <td align="" valign="" colspan="1" rowspan="3" bgcolor="#ffffff"> <p>50<br> (1 RCT) </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>ââââ<br><b>very low</b><sup>2</sup></p> </td> <td align="" valign="" colspan="1" rowspan="3" bgcolor="#ffffff"> <p>Single study assessing tongue protectors<br> No data were available to estimate longâterm change in QoL, or its surrogate markers: anxiety or depression </p> </td> </tr>
<tr class="separated">
<td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Change in QoL â anxiety:</b> shortâterm (â¤ 3 months) </p> <p>â Mean HAD anxiety score (Scale 0â21: lower better)</p> </td> <td align="" valign="" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>11.04</p> </td> <td align="" valign="" colspan="1" rowspan="1" class="table-tint table-highlight"> <p><b>0.16 higher</b> (3.19 lower to 3.51 higher) </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>â</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>ââââ<br><b>very low</b><sup>3</sup></p> </td> </tr>
<tr class="separated">
<td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Change in QoL â depression:</b> shortâterm (â¤ 3 months) </p> <p>â Mean HAD depression score (Scale 0â21: lower better)</p> </td> <td align="" valign="" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>8.92</p> </td> <td align="" valign="" colspan="1" rowspan="1" class="table-tint table-highlight"> <p><b>0.64 lower</b> (3.98 lower to 2.70 higher) </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>â</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>ââââ<br><b>very low</b><sup>4</sup></p> </td> </tr>
<tr class="separated">
<td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Change in taste</b> </p> </td> <td align="" valign="" colspan="6" rowspan="1" class="table-tint table-highlight"> <p>No included studies reported change in taste</p> </td> </tr>
<tr class="separated">
<td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Change in feeling of dryness</b> </p> </td> <td align="" valign="" colspan="6" rowspan="1" class="table-tint table-highlight"> <p>No included studies reported change in feeling of dryness</p> </td> </tr>
<tr class="separated">
<td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Adverse effects</b> </p> </td> <td align="" valign="" colspan="3" rowspan="1" class="table-tint table-highlight"> <p>The single study narratively reported that no adverse events occurred from the use of tongue protectors </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>50<br> (1 RCT) </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>ââââ<br><b>low</b><sup>5</sup></p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> </tr>
<tr class="separated">
<td align="" valign="" colspan="7" rowspan="1" bgcolor="#ffffff"> <p>*The basis for the <b>assumed risk</b> is provided in footnotes. The <b>corresponding risk</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI)<br><b>CI:</b> confidence interval; <b>HAD:</b> Hospital Anxiety and Depression scale; <b>OHIPâ49:</b> Oral Health Impact Profileâ49; <b>OIS:</b> optimal information size; <b>RCT:</b> randomised controlled trial; <b>VAS:</b> visual analogue scale </p> </td> </tr>
<tr class="separated">
<td align="" valign="" colspan="7" rowspan="1" bgcolor="#ffffff"> <p>GRADE Working Group grades of evidence<br><b>High quality:</b> further research is very unlikely to change our confidence in the estimate of effect<br><b>Moderate quality:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate<br><b>Low quality:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate<br><b>Very low quality:</b> we are very uncertain about the estimate </p> </td> </tr>
</tbody>
<tfoot><tr>
<td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Assumed placebo risk based on mean placebo group pain score at shortâterm (â¤ 3 months) followâup; downgraded twice due to serious concerns of risk of bias, relating to blinding and potential confounding influence of participants in receipt of anxiolytics; downgraded once due to imprecision: OIS not met.<br><sup>2</sup>Assumed placebo risk based on mean placebo group quality of life score at shortâterm (â¤ 3 months) followâup; downgraded twice due to serious concerns of risk of bias, relating to blinding and potential confounding influence of participants in receipt of anxiolytics; downgraded twice due to imprecision: OIS not met, and 95% CI includes no effect.<br><sup>3</sup>Assumed placebo risk based on mean placebo group anxiety score at shortâterm (â¤ 3 months) followâup; downgraded twice due to serious concerns of risk of bias, relating to blinding and potential confounding influence of participants in receipt of anxiolytics; downgraded twice due to imprecision: OIS not met, and 95% CI includes no effect; downgraded once due to indirectness: use of surrogate measure.<br><sup>4</sup>Assumed placebo risk based on mean placebo group depression score at shortâterm (â¤ 3 months) followâup; downgraded twice due to serious concerns of risk of bias, relating to blinding and potential confounding influence of participants in receipt of anxiolytics; downgraded twice due to imprecision: OIS not met, and 95% CI includes no effect; downgraded once due to indirectness: use of surrogate measure.<br><sup>5</sup>Downgraded twice due to serious concerns of risk of bias, relating to blinding and potential confounding influence of participants in receipt of anxiolytics; downgraded once due to imprecision: OIS not met. </p> </div> </td> </tr></tfoot>
</table>
</div> <div class="table" id="CD002779-tbl-0008"> <a href="#0" class="open-table-viewer open-in-figure-viewer">Open in table viewer</a><div class="table-heading">
<span class="table-label">Summary of findings 8.</span>Â <span class="table-title">Psychological therapies versus placebo for treating people with burning mouth syndrome</span>
</div>
<table class="summary-of-findings framed">
<tbody>
<tr class="table-header separated">
<td align="" valign="" colspan="7" rowspan="1" class="table-header"> <p><b> Psychological therapies compared with placebo for treating burning mouth syndrome</b> </p> </td> </tr>
<tr class="separated">
<td align="" valign="" colspan="7" rowspan="1" bgcolor="#ffffff"> <p><b>Patient or population:</b> people diagnosed with burning mouth syndrome </p> <p><b>Settings:</b> secondary care </p> <p><b>Intervention:</b> psychological therapies (cognitive therapy) </p> <p><b>Comparison:</b> placebo </p> </td> </tr>
<tr class="table-header separated">
<td align="" valign="top" colspan="1" rowspan="3" class="table-header"> <p><b>Outcomes</b> </p> </td> <td align="" valign="top" colspan="2" rowspan="1" class="table-tint table-highlight"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </td> <td align="" valign="top" colspan="1" rowspan="3" class="table-header"> <p><b>Relative effect<br> (95% CI)</b> </p> </td> <td align="" valign="top" colspan="1" rowspan="3" class="table-header"> <p><b>Number of participants<br> (studies)</b> </p> </td> <td align="" valign="top" colspan="1" rowspan="3" class="table-header"> <p><b>Quality of the evidence<br> (GRADE)</b> </p> </td> <td align="" valign="top" colspan="1" rowspan="3" class="table-header"> <p><b>Comments</b> </p> </td> </tr>
<tr class="table-header separated">
<td align="" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p><b>Assumed risk</b> </p> </td> <td align="" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p><b>Corresponding risk</b> </p> </td> </tr>
<tr class="table-header separated">
<td align="" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p><b>Placebo</b> </p> </td> <td align="" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p><b> Psychological therapies</b> </p> </td> </tr>
<tr class="separated">
<td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Symptom relief:</b> longâterm (&gt; 3 to â¤ 6 months) </p> <p>â Mean VAS pain score (Scale 1â7: lower better)</p> </td> <td align="" valign="" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>4.6</p> </td> <td align="" valign="" colspan="1" rowspan="1" class="table-tint table-highlight"> <p><b>3.20 lower</b> (4.22 to 2.18 lower) </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>â</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>30<br> (1 RCT) </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>ââââ<br><b>very low</b><sup>1</sup></p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Single study assessing cognitive therapy<br> No data was available to estimate shortâterm symptom relief<br> No data was available to estimate the effect of other psychological therapies </p> </td> </tr>
<tr class="separated">
<td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Change in quality of life (QoL)</b> </p> </td> <td align="" valign="" colspan="6" rowspan="1" class="table-tint table-highlight"> <p>No included study reported change in QoL</p> </td> </tr>
<tr class="separated">
<td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Change in taste</b> </p> </td> <td align="" valign="" colspan="6" rowspan="1" class="table-tint table-highlight"> <p>No included study reported change in taste</p> </td> </tr>
<tr class="separated">
<td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Change in feeling of dryness</b> </p> </td> <td align="" valign="" colspan="6" rowspan="1" class="table-tint table-highlight"> <p>No included study reported change in feeling of dryness</p> </td> </tr>
<tr class="separated">
<td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Adverse effects</b> </p> </td> <td align="" valign="" colspan="6" rowspan="1" class="table-tint table-highlight"> <p>No included study reported the occurrence of adverse events</p> </td> </tr>
<tr class="separated">
<td align="" valign="" colspan="7" rowspan="1" bgcolor="#ffffff"> <p>*The basis for the <b>assumed risk</b> is provided in footnotes. The <b>corresponding risk</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI)<br><b>CI:</b> confidence interval; <b>OIS:</b> optimal information size; <b>RCT:</b> randomised controlled trial; <b>VAS:</b> visual analogue scale </p> </td> </tr>
<tr class="separated">
<td align="" valign="" colspan="7" rowspan="1" bgcolor="#ffffff"> <p>GRADE Working Group grades of evidence<br><b>High quality:</b> further research is very unlikely to change our confidence in the estimate of effect<br><b>Moderate quality:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate<br><b>Low quality:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate<br><b>Very low quality:</b> we are very uncertain about the estimate </p> </td> </tr>
</tbody>
<tfoot><tr>
<td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Assumed placebo risk based on mean placebo group pain score at longâterm (&gt; 3 to â¤ 6 months) followâup; downgraded twice due to serious concerns of risk of bias, relating to blinding and lack of baseline data; downgraded once due to indirectness: concerns relating to applicability, only 1 type of psychological therapy assessed, effects of other psychological therapies may differ; downgraded once due to imprecision: OIS not met. </p> </div> </td> </tr></tfoot>
</table>
</div> <div class="table" id="CD002779-tbl-0009"> <a href="#0" class="open-table-viewer open-in-figure-viewer">Open in table viewer</a><div class="table-heading">
<span class="table-label">Summary of findings 9.</span>Â <span class="table-title">Topical treatments versus placebo for treating people with burning mouth syndrome</span>
</div>
<table class="summary-of-findings framed">
<tbody>
<tr class="table-header separated">
<td align="" valign="" colspan="7" rowspan="1" class="table-header"> <p><b> Topical treatments compared with placebo for treating burning mouth syndrome</b> </p> </td> </tr>
<tr class="separated">
<td align="" valign="" colspan="7" rowspan="1" bgcolor="#ffffff"> <p><b>Patient or population:</b> people diagnosed with burning mouth syndrome </p> <p><b>Settings:</b> secondary care </p> <p><b>Intervention:</b> topical treatments (benzydamine hydrochloride oral rinse, lactoperoxidase oral rinse (Biotene), topical urea (10%), capsaicin oral rinse) </p> <p><b>Comparison:</b> placebo </p> </td> </tr>
<tr class="table-header separated">
<td align="" valign="top" colspan="1" rowspan="3" class="table-header"> <p><b>Outcomes</b> </p> </td> <td align="" valign="top" colspan="2" rowspan="1" class="table-tint table-highlight"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </td> <td align="" valign="top" colspan="1" rowspan="3" class="table-header"> <p><b>Relative effect<br> (95% CI)</b> </p> </td> <td align="" valign="top" colspan="1" rowspan="3" class="table-header"> <p><b>Number of participants<br> (studies)</b> </p> </td> <td align="" valign="top" colspan="1" rowspan="3" class="table-header"> <p><b>Quality of the evidence<br> (GRADE)</b> </p> </td> <td align="" valign="top" colspan="1" rowspan="3" class="table-header"> <p><b>Comments</b> </p> </td> </tr>
<tr class="table-header separated">
<td align="" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p><b>Assumed risk</b> </p> </td> <td align="" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p><b>Corresponding risk</b> </p> </td> </tr>
<tr class="table-header separated">
<td align="" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p><b>Placebo</b> </p> </td> <td align="" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p><b>Topical treatments</b> </p> </td> </tr>
<tr class="separated">
<td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Symptom relief:</b> shortâterm (â¤ 3 months) </p> </td> <td align="" valign="" colspan="3" rowspan="1" class="table-tint table-highlight"> <p>There is insufficient or contradictory evidence regarding the benefit of any of the evaluated topical treatments over placebo to evaluate shortâterm symptom relief </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>150</p> <p>(4 RCTs)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>ââââ<br><b>very low</b><sup>1</sup></p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Interventions evaluated for shortâterm symptom relief included:</p> <p> </p>
<ul id="CD002779-list-0003">
<li> <p>benzydamine hydrochloride oral rinse (1 RCT)</p> </li> <li> <p>lactoperoxidase oral rinse (Biotene) (2 RCTs)</p> </li> <li> <p>topical urea (10%) (1 RCT)</p> </li> <li> <p>capsaicin oral rinse (1 RCT)</p> </li> </ul>
<p></p> <p>The mean VAS pain score (scale 0â10: lower better) for <b>longâterm symptom relief</b> (&gt; 3 to â¤ 6 months) was <b>2.60 lower</b> (5.11 to 0.09 lower) for people treated with capsaicin oral rinse than the placebo group (1 RCT, 18 participants)<br> No evidence of longâterm symptom relief from a single study assessing lactoperoxidase oral rinse (Biotene): mean VAS score in intervention group was 1.50 lower than people treated with placebo (3.91 lower to 0.91 higher) (1 RCT, 18 participants) </p> </td> </tr>
<tr class="separated">
<td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Change in quality of life (QoL)</b> </p> </td> <td align="" valign="" colspan="6" rowspan="1" class="table-tint table-highlight"> <p>No included studies reported change in QoL</p> </td> </tr>
<tr class="separated">
<td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Change in taste:</b> shortâterm (â¤ 3 months) </p> <p>â Mean Quantitative Sensory Testing (QST) score: gustative threshold (Scale: unknown)</p> </td> <td align="" valign="" colspan="3" rowspan="1" class="table-tint table-highlight"> <p>A single study narratively reported that there was no difference in shortâterm gustation thresholds </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>38</p> <p>(1 RCT)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>ââââ<br><b>very low</b><sup>2</sup></p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Single study assessing topical urea (10%)<br> No data were available to estimate longâterm change in taste<br> No data were available to estimate the effect of other topical treatments </p> </td> </tr>
<tr class="separated">
<td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Change in feeling of dryness:</b> </p> <p>shortâterm (â¤ 3 months)</p> <p>â Xerostomia questionnaire (Scale 1â5: lower better)</p> </td> <td align="" valign="" colspan="3" rowspan="1" class="table-tint table-highlight"> <p>A single study narratively reported that there was no difference in shortâterm xerostomia questionnaire assessment before or after treatment </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>38</p> <p>(1 RCT)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>ââââ<br><b>very low</b><sup>3</sup></p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Single study assessing topical urea (10%)<br> No data were available to estimate longâterm change in feeling of dryness<br> No data were available to estimate the effect of other topical treatments </p> </td> </tr>
<tr class="separated">
<td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Adverse effects</b> </p> </td> <td align="" valign="" colspan="3" rowspan="1" class="table-tint table-highlight"> <p>A single study narratively reported that no adverse events occurred from the use of benzydamine hydrochloride oral rinse </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>20<br> (1 RCT) </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>ââââ<br><b>very low</b><sup>4</sup></p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No data were available to estimate the effect of other topical treatments</p> </td> </tr>
<tr class="separated">
<td align="" valign="" colspan="7" rowspan="1" bgcolor="#ffffff"> <p>*The basis for the <b>assumed risk</b> is provided in footnotes. The <b>corresponding risk</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI)<br><b>CI:</b> confidence interval; <b>OIS:</b> optimal information size; <b>RCT:</b> randomised controlled trial; <b>VAS:</b> visual analogue scale </p> </td> </tr>
<tr class="separated">
<td align="" valign="" colspan="7" rowspan="1" bgcolor="#ffffff"> <p>GRADE Working Group grades of evidence<br><b>High quality:</b> further research is very unlikely to change our confidence in the estimate of effect<br><b>Moderate quality:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate<br><b>Low quality:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate<br><b>Very low quality:</b> we are very uncertain about the estimate </p> </td> </tr>
</tbody>
<tfoot><tr>
<td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Downgraded twice due to high risk of bias across multiple domains; downgraded twice due to inconsistency between, and within, subgroups; downgraded once due to imprecision: OIS not met; 1 RCT (<a href="./references#CD002779-bbs2-0015">Marino 2010</a>) contributes to 2 subgroups: capsaicin oral rinse and lactoperoxidase oral rinse (Biotene).<br><sup>2</sup>Downgraded twice due to high risk of bias relating to attrition and selective reporting; downgraded once due to indirectness: concerns relating to applicability, only 1 type of topical therapy assessed, effects of other topical therapies may differ; downgraded once due to imprecision: OIS not met.<br><sup>3</sup>Downgraded twice due to high risk of bias relating to attrition and selective reporting; downgraded once for indirectness: concerns relating to applicability, only 1 type of topical therapy assessed, effects of other topical therapies may differ; downgraded once due to imprecision: OIS not met.<br><sup>4</sup>Downgraded once due to unclear risk of bias across multiple domains; downgraded once due to indirectness: concerns relating to applicability, only 1 type of topical therapy assessed, effects of other topical therapies may differ; downgraded once due to imprecision: OIS not met. </p> </div> </td> </tr></tfoot>
</table>
</div> </section></section></body></html></body></html>
